Articles

February 7, 2012

2011 Review and Outlook for Biotechnology in 2012

January 25, 2012 By MD Becker Partners Leave a Comment

Our favorable outlook for the biotechnology industry remains intact for 2012 and is based on several key drivers

Filed Under: Articles Tagged With: 2011, 2012, Access to Capital, Akorn, AKRX, BDSI, BioDelivery Sciences, biotechnology, BMY, Bristol-Myers Squibb, Canaan Partners, consolidation, defensive sector, Dendreon, DNDN, Economic Driver, Endo Pharmaceuticals, ENDP, FDA, Flagship Ventures, HGSI, Human Genome Sciences, Inc., Inhibitex, INHX, ISTA, ISTA Pharmaceuticals, M&A, MDVN, Medivation, NASDAQ, New Drug Approvals, outlook, PhRMA, Pipeline, Review, RHHBY, roche, Valeant Pharmaceuticals, Vivo Ventures, VRX, Xenon Pharmaceuticals

2012 Preview: Cancer Immunotherapy Catalysts

December 14, 2011 By MD Becker Partners 1 Comment

MD Becker Partners' Life Science Digest: 2012 graphic

2012 represents a period with robust news flow for emerging immuno-oncology companies

Filed Under: Articles Tagged With: AE37, AGEN, Agenus, Allovectin, Amgen, AMGN, Antigen Express, BAVA, Bavarian Nordic, BMY, Bristol-Myers Squibb, cancer vaccine, castrate-resistant prostate cancer, CELG, Celgene, Celldex Therapeutics, CLDX, cv-301, Dendreon, DNDN, Generex, GlaxoSmithKline, GlobeImmune, GNBT, gp100, GSK, HyperAcute, Idera Pharmaceuticals, IDRA, immunotherapy, IMO-2055, ipilimumab, Jennerex, JX-594, MAGE-A3, melanoma, NewLink Genetics, NLNK, NSCLC, Oncothyreon, OncoVex, ONTY, pancreatic cancer, panvac, PROSTVAC, Provenge, QS-21, sipuleucel-T, Stimuvax, TG4010, transgene, Vical, VICL, Yervoy

Baker’s Dozen Trying to Beat the Odds in Pancreatic Cancer

October 23, 2011 By MD Becker Partners 1 Comment

November marks Pancreatic Cancer Awareness Month – a baker’s dozen are trying to beat the odds in treating the disease.

Filed Under: Articles Tagged With: 2011 Nobel Prize in Medicine, AAPL, Abraxane, Aduro BioTech, Afinitor, Algenpantucel-L, American Cancer Society, AMG 479, Amgen, AMGN, Apple, Astellas Pharma, Bayer Schering Pharma, CELG, Celgene Corporation, Clovis Oncology, CO-101, CRS-207, Eli Lilly, erlotinib, everolimus, gemcitabine, Gemzar, GlobeImmune, hENT1 protein, IMMU, Immunomedics, INFI, Infinity Pharma, IPI-926, islet cell tumors, LLY, neuroendocrine tumors of pancreatic origin, NewLink Genetics Corporation, Novartis, Novartis AG, Oncolytics Biotech, ONCY, pancreatic cancer, pancreatic NET, Patrick Swayze, Ralph Steinman, Seattle Genetics, Steve Jobs, Tarceva, TH-302, THLD, Threshold Pharmaceuticals

Adjuvants May Hold Key to Unlocking Cancer Immunotherapy Revolution

September 18, 2011 By MD Becker Partners Leave a Comment

MD Becker Partners' Life Science Digest: Adjuvants

Often overlooked, adjuvants can be an essential part of an effective vaccine and could help advance the field of cancer immunotherapy even further.

Filed Under: Articles Tagged With: 3M Company, adjuvant, AE37, AGEN, Agenus, aluminum salts, Antigen Express, antigen-specific cancer immunotherapeutic, AS15, BARDA, Biomedical Advanced Research and Development Authority, BMY, Bristol-Myers Squibb, cancer immunotherapy, Cationic Lipid-DNA Complex, CDX-1401, Celldex Therapeutics, Cervarix, CLDX, Colby Pharmaceutical Company, Corixa Corporation, CpG, CyMVectin, Dendreon Corporation, DNDN, Generex Biotechnology, GLA, GlaxoSmithKline, glucopyranosyl lipid A, GNBT, GSK, Idera Pharmaceuticals, IDRA, Ii-Key hybrid technology, Immune Design Corporation, IMO-2055, ipilimumab, Juvaris BioTherapeutics, JVRS-100, MAGE-A3, MF59, MMM, monophosphoryl lipid A, Mosquirix, MPL, pandemic influenza, Provenge, QS-21, Quillaja saponaria, resiquimod, saponin, sipuleucel-T, squalene, TLR, toll-like receptor, Vaxfectin, Vical Inc., VICL, Yervoy

Advances in Radiation Therapy for Cancer

July 27, 2011 By MD Becker Partners 1 Comment

Following the introduction of targeted agents beginning in the late 1990s, there is a common misconception that the use of older cancer therapies, such as radiation, is on the decline.

Filed Under: Articles Tagged With: Acute radiation syndrome, AEOL-10150, Aeolus Pharmaceuticals, ALS, American Cancer Society, amifostine, amyotrophic lateral sclerosis, Anti-radiation Drug Development Program, antioxidant, AstraZeneca, AZN, BARDA, Biomedical Advanced Research and Development Authority, brachytherapy, CBLB502, Cellerant Therapeutics, cisplatin, Cleveland BioLabs, CLT-008, conformal radiotherapy, dose limiting toxicity, Ethyol, Ex-RAD, external-beam radiation, Fukushima, hypotension, image-guided radiotherapy, IMRT, intensity-modulated radiotherapy, ionizing radiation, Japan, metalloporphyrin, NASDAQ: CBLI, nuclear reactors, ON 01210.Na, Onconova Therapeutics, OTCQB: AOLS, ovarian cancer, proton radiotherapy, radiation pneumonitis, radiation protecting compounds, radiation therapy, radiopharmaceuticals, radioprotectants, radiotherapy, reactive oxygen species, ROS, SOD, stress-induced apoptosis, superoxide dismutase, U.S. Army Research and Development Command, U.S. Bioscience, University of Rochester

2011 Review and Outlook for Biotechnology in 2012

2012 Preview: Cancer Immunotherapy Catalysts

Baker’s Dozen Trying to Beat the Odds in Pancreatic Cancer

Adjuvants May Hold Key to Unlocking Cancer Immunotherapy Revolution

Advances in Radiation Therapy for Cancer

Download the Life Science Digest App

Featured Video

About Life Science Digest

Like Us on Facebook

2011 Review and Outlook for Biotechnology in 2012

2012 Preview: Cancer Immunotherapy Catalysts

Baker’s Dozen Trying to Beat the Odds in Pancreatic Cancer

Adjuvants May Hold Key to Unlocking Cancer Immunotherapy Revolution

Advances in Radiation Therapy for Cancer

Download the Life Science Digest App

Follow MD Becker Partners

Featured Video

About Life Science Digest

Article Tag Cloud

Like Us on Facebook